Screener
Xenon Pharmaceuticals XENE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of property, plant and equipment | (408) | (200) |
| Purchases of marketable securities | (996,034) | (220,055) |
| Proceeds from marketable securities | 257,922 | 337,025 |
| Net cash provided by (used in) investing activities | (738,520) | 116,770 |
| Financing activities: | ||
| Proceeds from offerings, net | 837,526 | — |
| Proceeds from exercise of stock options | 5,513 | 1,216 |
| Net cash provided by financing activities | 843,039 | 1,216 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's investing cash flow?
- Xenon Pharmaceuticals (XENE) reported investing cash flow of -$331.24M in Q2 2026.
- How has Xenon Pharmaceuticals's investing cash flow changed year-over-year?
- Xenon Pharmaceuticals's investing cash flow decreased by 502.7% year-over-year, from $82.26M to -$331.24M.
- What is the long-term trend for Xenon Pharmaceuticals's investing cash flow?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's investing cash flow has grown at a -9.6% compound annual growth rate (CAGR), from -$294.72M to $218M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Xenon Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude